IS5108A - Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, aðferð við að framleiða lyfjablönduna og notkun hennar - Google Patents

Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, aðferð við að framleiða lyfjablönduna og notkun hennar

Info

Publication number
IS5108A
IS5108A IS5108A IS5108A IS5108A IS 5108 A IS5108 A IS 5108A IS 5108 A IS5108 A IS 5108A IS 5108 A IS5108 A IS 5108A IS 5108 A IS5108 A IS 5108A
Authority
IS
Iceland
Prior art keywords
preparation
bulk
mass
inhalation formulation
new inhalation
Prior art date
Application number
IS5108A
Other languages
English (en)
Other versions
IS2788B (is
Inventor
Trofast Jan
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS5108A publication Critical patent/IS5108A/is
Publication of IS2788B publication Critical patent/IS2788B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5108A 1997-01-20 1999-07-06 Búdesóníð- / formóterólefnablanda til innöndunar með lausa þéttni frá 0,30 til 0,36 g/ml, aðferð við að framleiða efnablönduna og notkun hennar IS2788B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700135A SE9700135D0 (sv) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000040 WO1998031352A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof

Publications (2)

Publication Number Publication Date
IS5108A true IS5108A (is) 1999-07-06
IS2788B IS2788B (is) 2012-06-15

Family

ID=20405455

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5108A IS2788B (is) 1997-01-20 1999-07-06 Búdesóníð- / formóterólefnablanda til innöndunar með lausa þéttni frá 0,30 til 0,36 g/ml, aðferð við að framleiða efnablönduna og notkun hennar

Country Status (34)

Country Link
US (2) US6030604A (is)
EP (1) EP1007017B2 (is)
JP (1) JP2010059181A (is)
KR (1) KR100528416B1 (is)
CN (1) CN1271993C (is)
AR (1) AR011080A1 (is)
AT (1) ATE288260T1 (is)
AU (1) AU731192B2 (is)
BR (1) BR9811249A (is)
CA (1) CA2277913C (is)
CZ (1) CZ296301B6 (is)
DE (1) DE69828886T3 (is)
DK (1) DK1007017T4 (is)
EE (1) EE03951B1 (is)
ES (1) ES2235311T5 (is)
HU (1) HU228622B1 (is)
ID (1) ID21865A (is)
IL (1) IL130838A (is)
IS (1) IS2788B (is)
MY (1) MY132999A (is)
NO (1) NO327426B1 (is)
NZ (1) NZ336594A (is)
PL (1) PL192115B1 (is)
PT (1) PT1007017E (is)
RU (1) RU2194497C2 (is)
SA (1) SA98180818B1 (is)
SE (1) SE9700135D0 (is)
SI (1) SI1007017T2 (is)
SK (1) SK283950B6 (is)
TR (1) TR199901690T2 (is)
TW (1) TW557217B (is)
UA (1) UA57764C2 (is)
WO (1) WO1998031352A1 (is)
ZA (1) ZA9878B (is)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
ES2207867T3 (es) * 1998-12-11 2004-06-01 Pharmachemie B.V. Preparacion farmaceutica para inhalacion de un opioide.
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6623760B1 (en) * 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
JP2002541213A (ja) * 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
CA2273585A1 (en) 1999-05-28 2000-11-28 Canpolar East Inc. Sensors for detecting changes in temperature, ph, chemical conditions, biological conditions, radiation, electrical field and pressure
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
DE19962926A1 (de) * 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
US20050222193A1 (en) * 2002-05-07 2005-10-06 Guido Hanauer Novel combination for the treatment of airway disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
AU2003293833B2 (en) * 2002-12-12 2009-10-01 Covis Pharma B.V. Combination medicament
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
EP1635844A1 (en) * 2003-05-22 2006-03-22 ALTANA Pharma AG Salmeterol and ciclesonide combination
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
DK1699434T3 (da) 2003-09-02 2011-05-30 Norton Healthcare Ltd Fremgangsmåde til fremstilling af et lægemiddel
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
PT1708991E (pt) * 2004-01-22 2007-12-14 Pfizer Derivados de sulfonamida para o tratamento de doenças
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
PE20060159A1 (es) * 2004-03-24 2006-04-04 Chiesi Farma Spa Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion
EP1740188A1 (en) * 2004-04-20 2007-01-10 Altana Pharma AG Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
CA2562386C (en) 2004-04-21 2014-11-18 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
KR20070100735A (ko) * 2004-12-17 2007-10-11 씨아이피엘에이 엘티디. 약학적 화합물 및 조성물
JP5156397B2 (ja) * 2005-02-10 2013-03-06 グラクソ グループ リミテッド 予備分級技術を用いて乳糖を製造する方法及びその乳糖から形成させた医薬製剤
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
AU2006272438B2 (en) * 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US8604080B2 (en) 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SI3106149T1 (sl) * 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BR112012017556A2 (pt) * 2010-01-15 2016-08-16 Lithera Inc formulações de torta liofilizada
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
KR20140025308A (ko) 2010-10-12 2014-03-04 시플라 리미티드 약학 조성물
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
KR20150002774A (ko) 2012-04-11 2015-01-07 시플라 리미티드 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
RU2510267C2 (ru) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
ES2662847T3 (es) 2013-07-01 2018-04-10 Arven Ilac Sanayi Ve Ticaret A.S. Formulaciones novedosas de inhalación
WO2019036483A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation AQUEOUS NEBULIZATION COMPOSITION
WO2020240350A1 (en) * 2019-05-24 2020-12-03 Glenmark Pharmaceutical Limited An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
CN117122585A (zh) * 2023-07-27 2023-11-28 宁波诺丁汉大学 一种通过振动混合制备干粉吸入团聚物处方制剂方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) † 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
ATE23272T1 (de) * 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) † 1988-11-01 1988-12-07 Fisons Plc Formulation
DE69034007T2 (de) * 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalationsvorrichtung für Trockenpulver
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
EP0441740B1 (de) † 1990-01-29 1993-09-22 Ciba-Geigy Ag Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
WO1993025198A1 (fr) † 1992-06-12 1993-12-23 Teijin Limited Poudre ultra-fine pour inhalation et production de cette poudre
DE69332291T2 (de) * 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
DE69415677T2 (de) * 1993-08-18 1999-06-10 Unilever N.V., Rotterdam Rasiermittel
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
IL111080A (en) * 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
GB9404945D0 (en) † 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation

Also Published As

Publication number Publication date
IS2788B (is) 2012-06-15
DK1007017T3 (da) 2005-05-02
HK1025515A1 (en) 2000-11-17
IL130838A (en) 2005-07-25
EP1007017A1 (en) 2000-06-14
DK1007017T4 (da) 2011-02-28
HUP0000714A2 (hu) 2000-08-28
EE9900295A (et) 2000-02-15
US6030604A (en) 2000-02-29
KR20000070188A (ko) 2000-11-25
SK95999A3 (en) 2000-01-18
CA2277913A1 (en) 1998-07-23
CN1271993C (zh) 2006-08-30
EP1007017B1 (en) 2005-02-02
MY132999A (en) 2007-10-31
EE03951B1 (et) 2003-02-17
TR199901690T2 (xx) 1999-09-21
AR011080A1 (es) 2000-08-02
PL192115B1 (pl) 2006-08-31
SA98180818B1 (ar) 2006-03-25
NO327426B1 (no) 2009-06-29
ES2235311T3 (es) 2005-07-01
CA2277913C (en) 2007-03-06
ZA9878B (en) 1998-07-20
DE69828886D1 (de) 2005-03-10
DE69828886T3 (de) 2011-06-01
JP2010059181A (ja) 2010-03-18
HUP0000714A3 (en) 2000-10-30
KR100528416B1 (ko) 2005-11-16
HU228622B1 (en) 2013-04-29
SI1007017T1 (en) 2005-06-30
PL334527A1 (en) 2000-02-28
CN1243436A (zh) 2000-02-02
TW557217B (en) 2003-10-11
NO993539D0 (no) 1999-07-19
PT1007017E (pt) 2005-05-31
IL130838A0 (en) 2001-01-28
BR9811249A (pt) 2000-09-05
CZ296301B6 (cs) 2006-02-15
SE9700135D0 (sv) 1997-01-20
DE69828886T2 (de) 2006-04-06
ES2235311T8 (es) 2011-05-13
ID21865A (id) 1999-08-05
US6287540B1 (en) 2001-09-11
UA57764C2 (uk) 2003-07-15
ATE288260T1 (de) 2005-02-15
JP4512204B2 (ja) 2010-07-28
SI1007017T2 (sl) 2011-03-31
JP2001508793A (ja) 2001-07-03
SK283950B6 (sk) 2004-05-04
ES2235311T5 (es) 2011-03-31
NO993539L (no) 1999-09-20
WO1998031352A1 (en) 1998-07-23
NZ336594A (en) 2001-01-26
CZ255799A3 (cs) 1999-10-13
AU731192B2 (en) 2001-03-29
EP1007017B2 (en) 2010-12-08
AU5785998A (en) 1998-08-07
RU2194497C2 (ru) 2002-12-20

Similar Documents

Publication Publication Date Title
IS5108A (is) Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, aðferð við að framleiða lyfjablönduna og notkun hennar
HUP0104579A3 (en) Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
HUP0100101A3 (en) Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use
FI962952A7 (fi) Delta 12,13-iso-taksolianalogit, niiden antineoplastinen käyttö ja nii tä sisältävät farmaseuttiset koostumukset
IS5526A (is) 11ß-Halógen-7alfa-setin estratríen, aðferð til framleiðslu á lyfjasamsetningum sem innihalda fyrrnefnd estratríen og notkun þeirra til framleiðslu á læknislyfjum
IL133672A0 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
PL344019A1 (en) Antibodies to cd23, derivatives thereof, and their therapeutic uses
IL140498A0 (en) Phenoxyacetic acid derivatives and medicinal compositions containing the same
GB2338244B (en) A microbe composition, a method to prepare the same and uses thereof
IS2076B (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
IL114980A0 (en) Cyclic urea derivatives, their preparation and pharmaceutical compositions containing them
HUP9801256A3 (en) 5'-deoxy-cytidine derivatives, preparation and use thereof and pharmaceutical compositions
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
IS3359A7 (is) ""2-guanidino-thiazol", aðferð til framleiðslu þess og notkun sem milliafurð við framleiðslu "famotidine" (N-sulfamyl-3-[(2-guanidinothiazol-4-yl)methylthio] -propionamidine)"
PL330762A1 (en) Pesticide preparation in the form of pellets
GB9211833D0 (en) Saccharide in the form of powder,and its preparation and uses
HUP0003357A3 (en) Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use
FI950728A7 (fi) 15-deoksispergualiinianalogit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkinnässä
IS4733A (is) Ný LH-RH mótlyf, framleiðsla þeirra og notkun, ásamt læknislyfjum sem innihalda samsetningarnar og framleiðsla þeirra
IL86407A0 (en) Organo-metal compositions,preparation and use
GB0017046D0 (en) Anti-ulcer pharmaceutical composition and the preparation thereof
NZ241309A (en) Heterocyclic amido prostaglandin analogues, preparation and pharmaceutical compositions thereof
FI973631L (fi) 1,3-diolipohjaiset eetterit, menetelmä 1,3-diolipohjaisten eetterien valmistamiseksi sekä eetterien käyttö
GB8909798D0 (en) Ws1128 substances,preparation thereof and pharmaceutical composition comprising the same